$8.84
0.57% yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock price

$8.84
+1.45 19.62% 1M
-4.16 32.00% 6M
-3.61 29.00% YTD
-2.18 19.78% 1Y
-2.30 20.65% 3Y
-7.62 46.29% 5Y
-62.54 87.62% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.05 0.57%
ISIN
US92556V1061
Symbol
VTRS
Sector
Industry

Key metrics

Market capitalization $10.38b
Enterprise Value $23.99b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 12.59
EV/Sales (TTM) EV/Sales 1.68
P/S ratio (TTM) P/S ratio 0.73
P/B ratio (TTM) P/B ratio 0.67
Dividend yield 5.43%
Last dividend (FY24) $0.48
Revenue growth (TTM) Revenue growth -6.88%
Revenue (TTM) Revenue $14.26b
EBIT (operating result TTM) EBIT $821.50m
Free Cash Flow (TTM) Free Cash Flow $1.91b
Cash position $850.80m
EPS (TTM) EPS $-3.18
P/E forward negative
P/S forward 0.75
EV/Sales forward 1.74
Short interest 4.68%
Show more

Is Viatris a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Viatris Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Viatris forecast:

4x Buy
36%
5x Hold
45%
2x Sell
18%

Analyst Opinions

11 Analysts have issued a Viatris forecast:

Buy
36%
Hold
45%
Sell
18%

Financial data from Viatris

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14,264 14,264
7% 7%
100%
- Direct Costs 8,718 8,718
1% 1%
61%
5,546 5,546
15% 15%
39%
- Selling and Administrative Expenses 1,030 1,030
3% 3%
7%
- Research and Development Expense 828 828
1% 1%
6%
3,688 3,688
21% 21%
26%
- Depreciation and Amortization 2,867 2,867
6% 6%
20%
EBIT (Operating Income) EBIT 822 822
59% 59%
6%
Net Profit -3,790 -3,790
6,656% 6,656%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Viatris directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viatris Stock News

Neutral
GlobeNewsWire
2 days ago
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).
Neutral
GlobeNewsWire
3 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options
Neutral
Seeking Alpha
3 days ago
Viatris Inc. (NASDAQ:VTRS ) BofA Securities 2025 Healthcare Conference May 13, 2025 8:00 PM ET Company Participants Doretta Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Jason Gerberry - BofA Securities Jason Gerberry Keep going here at the BofA Annual Healthcare Conference, and our last company presenter of the day, Viatris. Joining us is Doretta Mistras, Chief...
More Viatris News

Company Profile

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Head office United States
CEO Scott Smith
Employees 32,000
Founded 2019
Website www.viatris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today